Aethlon Medical (NASDAQ:AEMD) Posts Earnings Results

Aethlon Medical (NASDAQ:AEMD) issued its quarterly earnings results on Thursday. The medical equipment provider reported ($2.60) earnings per share for the quarter, beating the consensus estimate of ($2.70) by $0.10, FiscalAI reports.

Aethlon Medical Price Performance

Shares of AEMD opened at $5.33 on Friday. The stock has a 50-day moving average of $5.06 and a 200-day moving average of $7.40. The company has a market cap of $3.78 million, a PE ratio of -0.15 and a beta of 1.27. Aethlon Medical has a one year low of $1.41 and a one year high of $25.66.

Analysts Set New Price Targets

Several research firms recently issued reports on AEMD. HC Wainwright restated a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a report on Saturday, October 17th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $1.50.

About Aethlon Medical

Aethlon Medical, Inc. is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles. The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.